Impedimed Ltd (ASX: IPD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Impedimed Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $62.85 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.03 billion
Earnings per share -0.011
Dividend per share N/A
Year To Date Return -40.38%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Impedimed Ltd (ASX: IPD)
    Latest News

    a woman
    ⏸️ Investing

    Impedimed Limited share price climbs higher on FDA clearance

    The Impedimed Limited (ASX:IPD) share price is up 4% today after receiving FDA clearance for its SOZO product.

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have climbed higher today

    The Cochlear Limited (ASX:COH) share price is one of four defying the market and climbing higher. Here’s what you need…

    Read more »

    a woman
    ⏸️ Investing

    The ImpediMed Limited share price has jumped: Here's why

    ImpediMed Limited (ASX:IPD) takes another big step forward

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares are ending the week deep in the red

    The GUD Holdings Limited (ASX:GUD) share price is one of four ending the week deep in the red. Here’s what…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have rocketed higher today

    The Appen Ltd (ASX: APX) share price is one of four defying the market and climbing higher today. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have started the week deep in the red

    The Auscann Group Holdings Ltd (ASX:AC8) share price is one of four to have taken a tumble today. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares surged higher today

    The S&P/ASX 200 (Index:^AXJO) (ASX:XJO) may have dropped lower, but that hasn’t stopped the Mesoblast limited (ASX:MSB) share price and…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have bolted higher today

    The Ardent Leisure Group (ASX:AAD) share price is one of four to have bolted higher today. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    5 explosive growth shares I will be watching in 2017

    Nearmap Ltd (ASX:NEA) and Bionomics Ltd (ASX:BNO) are two of five explosive growth shares I’ll be watching in 2017.

    Read more »

    a woman
    ⏸️ Investing

    4 small-cap shares I think could be set to soar in 2017

    Capilano Honey Ltd (ASX:CZZ) is one of four small cap shares which I think have the potential to soar. Here…

    Read more »

    a woman
    ⏸️ Investing

    3 game-changing companies to buy today

    Freelancer Ltd (ASX:FLN) is one of three game-changing shares which I think investors should pay close attention to today.

    Read more »

    a woman
    ⏸️ Investing

    Broker tips 9 small cap stars to buy in October

    According to analysts at Morgans, Bellamy's Australia Ltd (ASX:BAL) is one of nine small caps you should be buying in…

    Read more »

    Frequently Asked Questions

    No, Impedimed does not pay shareholder dividends at this time.

    Impedimed Limited listed on the ASX on 24 October 2007.

    IPD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Impedimed Ltd

    Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.

    The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.

    As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America. 

    IPD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Jun 2025 $0.03 $0.00 0.00% 1,691,082 $0.03 $0.03 $0.03
    19 Jun 2025 $0.03 $0.00 0.00% 1,125,639 $0.03 $0.03 $0.03
    18 Jun 2025 $0.03 $0.00 0.00% 4,626,780 $0.03 $0.03 $0.03
    17 Jun 2025 $0.03 $0.00 0.00% 3,800,039 $0.03 $0.03 $0.03
    16 Jun 2025 $0.03 $0.00 0.00% 1,405,798 $0.03 $0.03 $0.03
    13 Jun 2025 $0.03 $0.00 0.00% 214,416 $0.03 $0.03 $0.03
    12 Jun 2025 $0.03 $0.00 0.00% 2,170,661 $0.03 $0.03 $0.03
    11 Jun 2025 $0.03 $0.00 0.00% 810,524 $0.03 $0.03 $0.03
    10 Jun 2025 $0.03 $0.00 0.00% 1,055,260 $0.03 $0.03 $0.03
    06 Jun 2025 $0.03 $0.00 0.00% 1,420,799 $0.03 $0.03 $0.03
    05 Jun 2025 $0.03 $0.00 0.00% 2,770,193 $0.03 $0.03 $0.03
    04 Jun 2025 $0.03 $0.00 0.00% 1,922,729 $0.03 $0.03 $0.03
    03 Jun 2025 $0.03 $0.00 0.00% 2,120,144 $0.03 $0.03 $0.03
    02 Jun 2025 $0.03 $0.00 0.00% 8,051,680 $0.03 $0.03 $0.03
    30 May 2025 $0.03 $0.00 0.00% 4,857,303 $0.03 $0.03 $0.03
    29 May 2025 $0.03 $0.00 0.00% 1,675,994 $0.03 $0.03 $0.03
    28 May 2025 $0.03 $0.00 0.00% 3,575,509 $0.03 $0.03 $0.03
    27 May 2025 $0.03 $0.00 0.00% 2,792,665 $0.03 $0.03 $0.03
    26 May 2025 $0.03 $0.00 0.00% 1,748,930 $0.03 $0.03 $0.03
    23 May 2025 $0.03 $0.00 0.00% 1,986,867 $0.03 $0.03 $0.03

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 May 2025 Christine Emmanuel-Donnelly Buy 306,446 $9,519
    On-market trade.
    22 Apr 2025 Christine Emmanuel-Donnelly Issued 349,412 $14,850
    Director remuneration.
    22 Apr 2025 Andrew Grant Issued 197,647 $8,399
    Director remuneration.
    22 Apr 2025 Fiona Bones Issued 197,647 $8,399
    Director remuneration.
    22 Apr 2025 Janelle Delaney Issued 197,647 $8,399
    Director remuneration.
    04 Mar 2025 Christine Emmanuel-Donnelly Buy 318,116 $13,414
    On-market trade.
    04 Mar 2025 Christine Emmanuel-Donnelly Buy 545,000 $20,832
    On-market trade.
    31 Jan 2025 Fiona Bones Issued 156,115 $8,400
    Director remuneration.
    31 Jan 2025 Christine Emmanuel-Donnelly Issued 275,988 $14,850
    Director remuneration.
    31 Jan 2025 Andrew Grant Issued 156,115 $8,400
    Director remuneration.
    31 Jan 2025 Janelle Delaney Issued 156,115 $8,400
    Director remuneration.
    23 Dec 2024 Fiona Bones Issued 152,468 $8,400
    Director remuneration.
    23 Dec 2024 Andrew Grant Issued 152,468 $8,400
    Director remuneration.
    23 Dec 2024 Janelle Delaney Issued 152,468 $8,400
    Director remuneration.
    23 Dec 2024 Christine Emmanuel-Donnelly Issued 269,542 $14,851
    Director remuneration.
    22 Nov 2024 Christine Emmanuel-Donnelly Buy 295,000 $15,915
    On-market trade.
    20 Nov 2024 Fiona Bones Buy 920,000 $49,276
    On-market trade.
    16 Oct 2024 Parmjot Bains Issued 8,500,000 $552,500
    Issue of securities. 8,500,000 Performance Rights
    16 Oct 2024 Parmjot Bains Issued 8,500,000 $552,500
    Issue of options.
    16 Oct 2024 McGregor Grant Issued 6,500,000 $422,500
    Issue of securities. 6,500,000 Performance Rights
    16 Oct 2024 McGregor Grant Issued 6,500,000 $422,500
    Issue of options.
    05 Sep 2024 Andrew Grant Buy 600,000 $28,530
    On-market trade.
    30 Aug 2024 Andrew Grant Buy 1,000,000 $49,600
    On-market trade.
    30 Aug 2024 Christine Emmanuel-Donnelly Buy 200,000 $10,000
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Parmjot Bains Managing DirectorChief Executive Officer Jan 2024
    Dr Bains is a medical doctor with more than 30 years of diverse healthcare experience including Pfizer and McKinsey across the United States, Asia, Middle East and Australia.
    Mr Andrew John Grant Non-Executive Director Sep 2023
    Mr Grant has spent more than 20 years in gaining understanding and experience working with key US customers and across global healthcare markets. He has Strategic planning experience and delivery in healthcare working with leading healthcare organisations globally, including McKinsey and ResMed. He is also a member of Risk Committee.
    Mr McGregor Grant Executive DirectorChief Financial Officer Feb 2024
    Mr Grant brings Broad commercial and financial experience in growing successful global medical device businesses, most recently Nanosonics Limited. He has Board administration, governance and investor relations experience.
    Ms Christine Emmanuel-Donnelly Non-Executive DirectorNon-Executive Chairman Sep 2023
    Ms Emmanuel-Donnelly brings 30 years in IP expertise through commercialisation and strategic in-house intellectual property roles. She has more than 4 years in Board and healthcare governance experience. She is a member of the Risk Committee.
    Ms Janelle Delaney Non-Executive Director Sep 2023
    Ms Delaney has 30 years of project management and execution at IBM, with responsibility for the quality of delivery across Asia Pacific's portfolio of several thousand projects. She is a member of Risk Committee.
    Ms Fiona Bones Non-Executive Director Jun 2024
    Ms Bones brings more than 30 years of experience in the finance, corporate governance and systems transformation. She has global governance experience gained as Vice President of Finance, International Controller of Google for 20 years. She is Chair of the Risk Committee.
    Ms Leanne Ralph Company Secretary Jan 2015
    -
    Steven Chen Chief Medical Officer
    -
    Leanne Ralph Company Secretary
    -
    Ashley Munoz Director Human Resources
    -
    Andrew Grant Executive Director VP Product Development & Customer Solutions
    -
    Julie Kuhlken Senior Director Downstream Marketing
    -
    Dennis Schlaht SVP R&D and Technology
    -
    Tim Benkovic SVP Sales & Customer Success
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 177,180,440 8.76%
    HSBC Custody Nominees (Australia) Limited 164,419,200 8.13%
    Jp Morgan Nominees Australia Pty Limited 148,941,253 7.36%
    National Nominees Limited 115,304,879 5.70%
    HSBC Custody Nominees (Australia) Limited i 55,570,348 2.75%
    BNP Paribas Noms Pty Ltd 34,426,377 1.70%
    Sunlora Pty Ltd 32,125,000 1.59%
    Moore Family Nominee Pty Ltd 30,000,000 1.48%
    Mr Hamish Alexander Jones 23,538,705 1.16%
    Mba Investments Pty Ltd 22,490,990 1.11%
    Mr Gregory Wayne Brown 20,300,000 1.00%
    Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken 19,000,000 0.94%
    Bnp Paribas Nominees Pty Ltd i 18,925,694 0.94%
    Pakasoluto Pty Limited 16,011,422 0.79%
    Mr Hsien Michael Soo 15,662,797 0.77%
    First Samuel Ltd Acn 086243567 15,281,508 0.76%
    HSBC Custody Nominees (Australia) Limited A/C 2 14,251,964 0.70%
    Bsd Pty Ltd 13,495,000 0.67%
    Hme Soo Holdings Pty Ltd 12,320,921 0.61%
    Bnp Paribas Nominees Pty Ltd ii 11,693,112 0.58%

    Profile

    since

    Note